Brief: Herantis Pharma H1 Net Loss Widens To EUR 4.5 Mln

Herantis Pharma Oyj

25/08/2020 07:10

Aug 25 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * H1 NET LOSS EUR 4.5 MILLION VERSUS LOSS EUR 3.3 MILLION
YEAR AGO
    * FOR LYMFACTIN, COMPANY WILL CONTINUE PREPARATIONS FOR A
PHASE
III CLINICAL STUDY WHILE EXPECTING PHASE II RESULTS IN Q1/2021
    * MAIN OBJECTIVE OF THIS FIRST-IN-HUMAN CLINICAL STUDY WITH
CDNF
IS TO DEMONSTRATE ITS SAFETY IN PATIENTS.
    * COVID-19 PANDEMIC MAY RESULT IN DELAYS IN COLLECTING
LYMFACTIN
PHASE II CLINICAL DATA I

Source text for Eikon:  ID:nWkr5V8vZt 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))